Press Release: Dako : Dako, an Agilent Technologies Company, Announces Availability of New Lung Cancer Test in Europe

CARPINTERIA, Calif.--(BUSINESS WIRE)--Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the commercial availability in the EU of a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. The diagnostic, known as PD-L1 IHC 28-8 pharmDx, was developed through a collaboration with Brist